Protocols›Cognitive & neuro›Calm & Sleep
← Protocols
Mitochondrial · MDPsLongevity · experimentalUnlicensed research

Cellular Energy & Longevity

Stack: MOTS-c + Humanin · the mitochondrial-derived peptide side of the longevity category
"A different longevity mechanism from the Epitalon/GHK-Cu foundation: mitochondrial-derived peptides. Exciting biology — MOTS-c behaves like an exercise mimetic in animals — but the honest reality is there are no human trials of giving either peptide. Endogenous levels track with ageing; injecting them is unproven."
GoalMitochondrial function / healthy-ageing (experimental)
Compounds2 · MOTS-c + Humanin
Human evidenceWeak — animal + human association only; no administration trials
StatusUK: unlicensed research chemicals — not controlled, legal to possess, but not approved medicines. No regulator has approved either for any use.
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
What’s actually established
MOTS-c
A 16-aa mitochondrial-derived peptide; an "exercise mimetic" in mice. In humans, endogenous levels decline with age and associate with muscle and metabolic markers — that’s association, not an administration trial.
Humanin
The first-described mitochondrial-derived peptide; neuroprotective in cell and animal models, with human levels associating with age and cognition. Again association, not administration.
Evidence it adds
Strong mechanism and human association data — but no trials of giving either peptide.
Basis: peer-reviewed preclinical + human observational
The clinically-developed cousin — SS-31
SS-31 / elamipretide
The one mitochondrial peptide with real clinical development. The FDA granted it accelerated approval in Sept 2025 (as Forzinity) — but only for Barth syndrome, an ultra-rare disease, and its broader mitochondrial Phase 3 trials missed their primary endpoints.
What it tells us
That mitochondrial-targeted peptides can clear an approval bar in one specific rare disease — not that they are proven for healthy ageing.
Evidence it adds
None for longevity. A cautionary reference point, not validation.
Basis: FDA accelerated approval (Barth syndrome only)
Grey-market / unsupervised use
Where / who
MOTS-c and Humanin are sold as research peptides, reconstituted for subcutaneous use; any dosing is entirely community-derived.
What changes
No human dosing has been established in trials; product identity, purity and dose are unverified.
Evidence it adds
None — unsupervised use has no trial basis at all here.
Basis: real-world sourcing — not a trial tier
Regulatory — read carefully
MHRA (UK)
Neither MOTS-c nor Humanin is a licensed medicine or a controlled drug — unlicensed research chemicals.
Elsewhere
No FDA/EMA approval for either. (SS-31 is approved only for Barth syndrome.)
What it means
Interesting biology, essentially no human administration evidence — the most speculative protocol here.
Basis: MHRA: unlicensed, not scheduled
Why this pairing

Longevity Foundations covers the telomere / skin / NAD⁺ angle — Epitalon, GHK-Cu, NAD⁺. This pairing is a different mechanism: mitochondrial-derived peptides (MDPs), the small peptides your own mitochondria encode. MOTS-c behaves like an exercise mimetic in animals and its endogenous levels fall with age; Humanin is neuroprotective in models and tracks with cognition. The honest framing, which matters here more than anywhere: the mechanism is genuinely interesting, but no published human trial has given either peptide for ageing or performance. Endogenous association is not proof that injecting them helps.

Members only · the actionable depth
See exactly how it's run
Doses, titration structure and what to monitor are part of membership. The provenance, evidence and status above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
MOTS-c
SubQ, cyclical (community)
Humanin
SubQ, cyclical (community)
Review
cycle / reassess
Any schedule here is community-derived — there is no trial-established human dosing for either peptide. Included to describe how they’re used in practice, explicitly not a prescription.
What's worth monitoring

The honest caveat dominates: there are no human administration trials, so both efficacy and long-term safety in people are essentially unknown. Reported short-term tolerability from community use is not a safety record, and product identity and purity are unverified. This is the most experimental protocol in the wellness set — a clinician conversation is the floor, and scepticism is warranted. General information, not medical advice.

Evidence
MOTS-c · metabolic / ageing Weak

Exercise-mimetic in mice; human levels decline with age (association). No administration trials.

Humanin · neuroprotection Weak

Neuroprotective in cell/animal models; human association with age and cognition. No administration trials.

SS-31 · context Barth only

Elamipretide is FDA-approved for Barth syndrome (2025); broader mito trials missed endpoints. No ageing evidence.

The honest point

Great mechanism, essentially no human administration evidence. Experimental — not a longevity solution.

Fast facts
Compounds

MOTS-c · Humanin (see also SS-31)

Routes

Subcutaneous (community)

UK strip

GREEN — legal to possess (unlicensed)